Durable Reductions in HbA1c, Body Weight Seen With Semaglutide
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 4, 2023 -- Use of once-weekly subcutaneous semaglutide is associated with sustained reductions in hemoglobin A1c (HbA1c) and body weight, according to a study presented at the annual meeting of the European Association for the Study of Diabetes, held from Oct. 2 to 6 in Hamburg, Germany.
Cheli Melzer-Cohen, from Maccabi Health Services in Tel Aviv, Israel, and colleagues examined the effect of subcutaneous semaglutide on HbA1c and weight reduction in a large cohort of adult patients treated for up to three years. Data were included for 23,442 patients (mean age, 62.2 years; mean weight, 94.1 kg; mean body mass index, 33.7 kg/m2; mean HbA1c, 7.6 percent).
The researchers found that among 75 percent of patients, the proportion of days covered (PDC) within the first six months was more than 60 percent. In the intent-to-treat analysis, there were significant reductions in HbA1c (by 0.77 percent to a mean of 6.82 percent) and in body weight (by 4.7 kg to a mean of 89.7 kg). The decreases in HbA1c and weight were more pronounced for glucagon-like peptide-1 receptor agonist (GLP-1-RA)-naive patients than those who had previously received GLP-1-RA (HbA1c, −0.87 versus −0.54 percent; weight, −5.51 versus −3.01 kg). Patients with PDC ≥60 versus <60 percent had greater reductions in both HbA1c and weight. In the intent-to-treat analysis, reductions in both HbA1c and weight were maintained over three years. In the as-treated analysis, the durable pattern of reduction was more evident.
"In this large real-world study, we were able to show durable reductions in HbA1c and body weight with emphasis on drug adherence," coauthor Avraham Karasik, M.D., also from Maccabi Health Services, said in a statement. "Data are in line with results in randomized controlled trials and show the long-term stable benefit of once-weekly semaglutide."
The study was funded by Novo Nordisk, the manufacturer of semaglutide.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.